Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E1 | Q9Y466 | 3/20 | 0.38 |
| ▸ | RORA | P35398 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3747991 | 0.93 | NSD2 (0.44) | SIRT2NSD2CYP11B1CYP11B2 | |
| SCHEMBL3706759 | 0.85 | CYP11B1 (0.35) | NR2E1RORASIRT2NSD2CYP11B1 | |
| SCHEMBL2203209 | 0.82 | CDC25B (0.46) | CYP1A2 | |
| SCHEMBL5682164 | 0.81 | CYP11B1 (0.43) | SIRT2CYP11B1CYP11B2CYP1A2ENPP2 | |
| SCHEMBL7641514 | 0.77 | P2RX7 (0.40) | SIRT2CYP11B1CYP11B2ENPP2 | |
| SCHEMBL1479176 | 0.77 | NAPRT (0.47) | SIRT2CYP11B1CYP11B2CYP1A2ENPP2 | |
| SCHEMBL670904 | 0.75 | CYP11B1 (0.43) | SIRT2CYP11B1CYP11B2ENPP2 | |
| SCHEMBL3751804 | 0.75 | KDM4E (0.38) | SIRT2ENPP2 | |
| SCHEMBL12510626 | 0.74 | SIRT2 (0.36) | SIRT2CYP11B1CYP11B2CYP1A2ENPP2 | |
| SCHEMBL23193358 | 0.73 | NCF1 (0.50) | NSD2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393800-B1 | PYRIDINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN INC (US) | 2014-10-08 | — | — | EP | disclosed |
| US-20110306635-A1 | PYRIDINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B AND /OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN ,INC. (US) | 2011-12-15 | — | — | US | disclosed |
| EP-2393800-A1 | PYRIDINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | Allergan, Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010091209-A1 | PYRIDINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20080221152-A1 | 4-(HETEROARYL-METHYL AND SUBSTITUTED HETEROARYL-METHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS | ALLERGAN, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221152-A1 | 4-(HETEROARYL-METHYL AND SUBSTITUTED HETEROARYL-METHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS | ALLERGAN, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221152-A1 | 4-(HETEROARYL-METHYL AND SUBSTITUTED HETEROARYL-METHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS | ALLERGAN, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-7399868-B2 | 4-(Heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists | ALLERGAN, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-7399868-B2 | 4-(Heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists | ALLERGAN, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-7399868-B2 | 4-(Heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists | ALLERGAN, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1791832-A1 | 4-(HETEROARYL-METHYL AND SUBSTITUTED HETEROARYL-METHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS | Allergan, Inc. (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006036507-A1 | 4-(HETEROARYL-METHYL AND SUBSTITUTED HETEROARYL-METHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS | ALLERGAN, INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069143-A1 | 4-(Heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists | ALLERGAN, INC. | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221152-A1 | 4-(HETEROARYL-METHYL AND SUBSTITUTED HETEROARYL-METHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS | ADRB2, ADRA2C, ADRA2A | NR2E1 237/4885RORA 192/4885SIRT2 1298/4885 |
| US-20110306635-A1 | PYRIDINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B AND /OR ALPHA 2C ADRENERGIC RECEPTORS | ADRA2C, ADRB2, ADRA2B | NR2E1 221/4885RORA 232/4885SIRT2 1378/4885 |
| US-20060069143-A1 | 4-(Heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists | ADRB2, ADRA2C, ADRA2A | NR2E1 261/4885RORA 276/4885SIRT2 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.